Trial Profile

Tislelizumab Combined With GEMOX (GOT) Applied as Neoadjuvant Regimen for Patients of Resectable Intrahepatic Cholangiocarcinoma With High-risk Factors of Recurrence: a Single Arm, Single Center, Prospective, Explorative Clinical Trail.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
Indications Cholangiocarcinoma
Focus Therapeutic Use
Acronyms GOT

11 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
11 Feb 2025 Planned primary completion date changed from 1 Oct 2024 to 30 Nov 2025.
06 Sep 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com